
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: Future of Bispecific Therapies for NHL
Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Advertisement
Video content above is prompted by the following:
- What do you perceive the future to look like for patients being treated with bispecific antibodies for non-Hodgkin lymphoma?
- What remain the key unmet needs?
- Do you have any clinical pearls for the community oncologist?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Real-World Data Confirm Alectinib's Edge Over Crizotinib in ALK+ NSCLC
5





























